等待開盤 11-19 09:30:00 美东时间
-0.170
-1.53%
Novocure receives an FDA Not Approvable Letter for Optune Mya in NSCLC brain metastases, citing unclear clinical benefit while finding no safety issues.
11-10 00:26
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
07-23 19:11
U.S. stocks traded higher on Thursday with the S&P 500 gaining 1% while tech shares surged 2.3%. Accenture stock tumbled 15% after weaker outlook.
06-19 01:02
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
06-18 22:09
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
NovoCure shares are popping Thursday following a major FDA approval that sent the stock soaring nearly 30% in Wednesday's after‑hours.
02-13 00:26
编者按:国际肺癌研究协会(IASLC)主办的2025年世界肺癌大会(WCLC 2025)于2025年9月6日在西班牙巴塞罗那盛大召开,作为肺癌及其他胸部恶性肿瘤...
2025-09-16 18:05
周一,医疗设备生产商Novocure Ltd.(NVCR.US)一度上涨约42%,创2023年1月份以来最大盘中涨幅。截至发稿,该股涨幅收窄至29.3%,报25.92美元。消息面上,最新研究结果表明,该公司针对胰腺癌的癌症疗法Tumor Treating Fields实现主要终点。 海量资讯、精准解读,尽在新浪财经APP 责任编辑:郭明煜
2024-12-02 23:52
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 再鼎医药(09688)早盘上涨4.32%,现报20.30港元,成交额3418.73万港元。 近日,再鼎医药合作伙伴Novocure(NVCR.US)宣布,美国食品药品监督管理局(FDA)已批准Optune Lua与PD-1/PD-L1抑制剂或多西他赛同时使用,用于治疗转移性非小细胞肺癌(mNSCLC)的成人患者,这些患者在接受含铂的治疗方案期间或之后出现了疾病进展。 海量资讯、精准解读,尽在新浪财经APP 责任编辑:卢昱君
2024-10-17 11:02